Roth Capital Starts Bionano Genomics (BNGO) at Buy

Roth Capital analyst David Solomon initiates coverage on Bionano Genomics (NASDAQ: BNGO) with a Buy rating and a price target of $12.00.

The analyst believes Saphyr is a differentiated tool for the company which generates novel & valuable information, which in turn makes it well-positioned to penetrate the large and rapidly-growing discovery research/cytogenetics industries. The analyst believes Saphyr could drive revenue growth to an inflection in 2020 and is forecasting instrument sales of nearly $60 million by 2023.

For an analyst ratings summary and ratings history on Bionano Genomics click here. For more ratings news on Bionano Genomics click here.

Shares of Bionano Genomics closed at $6.31 yesterday.

You May Also Be Interested In

• Northland Starts Nephros (NEPH) at Market Perform
• Desjardins Starts Tourmaline Oil Corp. (TOU:CN) (TRMLF) at Hold
• Desjardins Starts Whitecap Resources Inc. (WCP:CN) (SPGYF) at Buy